Olverembatinib

SKU: orb1304570

Description

Olverembatinib

Research Area

Cardiovascular Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	1257628-77-5
MW	532.56
Purity	98.53%
Formula	C₂₉H₂₇F₃N₆O
SMILES	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1
Target	Bcr-Abl
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (7.51 mM);DMSO:245 mg/mL (460.04 mM)

Bioactivity

−

Target IC50	BCR-ABL:0.34 nM\|BCR-ABL:0.68 nM
In Vitro	GZD824 potently inhibits the growth of Ba/F3 cells expressing wildtype Bcr-Abl with IC50 of 1.0 nM. Highly consistent with biochemical kinase inhibition and tight protein binding affinity, GZD824 also strongly inhibits the proliferation of Ba/F3 cells expressing Bcr-AblT315I mutant and 14 other resistance-relevant Bcr-Abl mutants. In addition, GZD824 efficiently suppresses the activation of Bcr-Abl as well as downstream Crkl and STAT5 in a concentration-dependent manner in K562 CML cells. Read more...
Cell Research	Cells in the logarithmic phase are plated in 96-well culture dishes. Twenty-four hours later, cells are treated with the corresponding compounds or vehicle control at the indicated concentration for 72 h. CCK-8 is added into the 96-well plates (10 μL/well) and incubated with the cells for 3 h. OD450 and OD650 are determined by a microplate reader. Absorbance rate (A) for each well is calculated as OD450 – OD650. The cell viability rate for each well is calculated as V% = (As – Ac)/(Ab – Ac) × 100%, and the data were further analyzed using Graphpad Prism5. The data are the mean value of the three experiments. As is the absorbance rate of the test compound well, Ac is the absorbance rate of the well without either cell or test compound, and Ab is the absorbance rate of the well with cell and vehicle control.(Only for Reference) Read more...

Storage & Handling

−

Storage	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Abl (E254K), BcrAbl, Bcr-Abl(T315I), Bcr-Abl, cluster, breakpoint, inhibit, imatinib, linase, nonphosphorylated, Olverembatinib, Inhibitor, HQP 1351, HQP1351, HQP-1351, GZD 824, GZD824, GZD-824, resistance, phosphorylated, region-Abelson,

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

51038269 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Olverembatinib (orb1304570)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	99.74%
CAS Number:	1421783-64-3
MW:	724.77
Formula:	C₂₉H₂₇F₃N₆O·2CH₄O₃S

Olverembatinib

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Olverembatinib dimesylate [orb1305496]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Olverembatinib (orb1304570)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors